Diagnostic Center of Acute Leukemia (DCAL), Institute of Pharmaceutical Biology, Goethe-University, Frankfurt am Main, Germany.
Department of Medicine, Hematology/Oncology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany.
Leukemia. 2023 Jun;37(6):1216-1233. doi: 10.1038/s41375-023-01895-z. Epub 2023 Apr 26.
KMT2A-rearranged acute lymphoblastic infant leukemia (KMT2A-r iALL) is associated with outsize risk of relapse and relapse mortality. We previously reported strong upregulation of the immediate early gene EGR3 in KMT2A::AFF1 iALL at relapse; now we provide analyses of the EGR3 regulome, which we assessed through binding and expression target analysis of an EGR3-overexpressing t(4;11) cell culture model. Our data identify EGR3 as a regulator of early B-lineage commitment. Principal component analysis of 50 KMT2A-r iALL patients at diagnosis and 18 at relapse provided strictly dichotomous separation of patients based on the expression of four B-lineage genes. Absence of B-lineage gene expression translates to more than two-fold poorer long-term event-free survival. In conclusion, our study presents four B-lineage genes with prognostic significance, suitable for gene expression-based risk stratification of KMT2A-r iALL patients.
KMT2A 重排急性淋巴细胞白血病(KMT2A-r iALL)与复发风险和复发死亡率增加有关。我们之前报道了在 KMT2A::AFF1 iALL 复发时,早期基因 EGR3 的强烈上调;现在我们提供了 EGR3 调节组的分析,我们通过对 EGR3 过表达 t(4;11)细胞培养模型的结合和表达靶标分析来评估 EGR3 调节组。我们的数据将 EGR3 鉴定为早期 B 细胞谱系决定的调节剂。对 50 名 KMT2A-r iALL 患者在诊断时和 18 名在复发时的主成分分析,根据四个 B 细胞谱系基因的表达严格地将患者分为两类。B 细胞谱系基因表达缺失意味着长期无事件生存率降低两倍以上。总之,我们的研究提出了四个具有预后意义的 B 细胞谱系基因,适合 KMT2A-r iALL 患者基于基因表达的风险分层。